limitation

Demonstration discussion: For the lecanemab record, the distinction between a statistically detectable treatment difference and a patient-meaningful change deserves careful discussion. I would also like to compare how missing outcomes and adverse-event monitoring were handled in the source report.

Paper mentions: 341a26ce-55f4-48ea-ad9c-15fc2f0dbcc3